Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG1105 IMPROVE-MPB study in transplant-ineligible newly diagnosed multiple myeloma
jRCTs031180097Phase 2Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of bortezomib, melphalan and prednisolone in multiple myeloma (MM) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Complete response rate. Started Jul 2013; status: completed.
02
Drugs
bortezomibmelphalanprednisolone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCTs031180097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180097.